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Mutations in parkin are currently recognized as the most common cause of familial Parkinsonism. Emerging
evidence also suggests that parkin expression variability may confer a risk for the development of the more
common, sporadic form of Parkinson’s disease (PD). Supporting this, we have recently demonstrated that
parkin solubility in the human brain becomes altered with age. As parkin apparently functions as a broad-
spectrum neuroprotectant, the resulting decrease in the availability of soluble parkin with age may underlie
the progressive susceptibility of the brain to stress. Interestingly, we also observed that many familial-PD
mutations of parkin alter its solubility in a manner that is highly reminiscent of our observations with the
aged brain. The converging effects on parkin brought about by aging and PD-causing mutations are probably
not trivial and suggest that environmental modulators affecting parkin solubility would increase an individ-
ual’s risk of developing PD. Using both cell culture and in vivo models, we demonstrate here that several PD-
linked stressors, including neurotoxins (MPP1, rotenone, 6-hydroxydopamine), paraquat, NO, dopamine and
iron, induce alterations in parkin solubility and result in its intracellular aggregation. Furthermore, the
depletion of soluble, functional forms of parkin is associated with reduced proteasomal activities and
increased cell death. Our results suggest that exogenously introduced stress as well as endogenous dopa-
mine could affect the native structure of parkin, promote its misfolding, and concomitantly compromise its
protective functions. Mechanistically, our results provide a link between the influence of environmental
and intrinsic factors and genetic susceptibilities in PD pathogenesis.
INTRODUCTION
Parkinson’s disease (PD) is the most common neurodegenera-
tive movement disorder characterized pathologically by the
rather selective loss of dopaminergic neurons in the substantia
nigra pars compacta (SNc) and the presence of intraneuronal
protein inclusions known as Lewy bodies (LB). Although
the molecular mechanism of dopaminergic neuronal loss in
the more common, sporadic form of PD is not well under-
stood, the recent focus on the study of genes linked to rare
inherited forms of PD has yielded significant insights into
the pathogenesis of sporadic PD (1–3). In particular, the
linkage of genetic mutations in the parkin gene to familial
Parkinsonism and the seminal discovery that parkin functions
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as a ubiquitin ligase associated with protein homeostasis have
helped position the ubiquitin proteasome system as a key focal
point in PD pathogenesis (1–4).
Mutations in parkin are currently recognized as one of the
most common cause of familial Parkinsonism. To date, the
descriptions of parkin-related PD include patients with homo-
zygous mutations, compound heterozygous mutations as well
as those with a single mutation (5). Although PD due to
parkin mutations is classically transmitted in an autosomal
recessive inheritance, the existence of patients with single
mutations raises the possibility of an expanded risk associated
with parkin haploinsufficiency (5–7). Supporting this possi-
bility is the recent association of parkin gene promoter with
late-onset PD (8). Parkin variability could thus be considered
as a risk factor for the development of PD.
The importance of parkin expression to neuronal survival is
probably related to the multitude of neuroprotective roles it
appears to serve (9). Parkin apparently confers protection to
neurons against a diversity of cellular insults including
manganese-induced cell death (10), a-synuclein toxicity (11),
proteasomal dysfunction (12), Pael-R (13) and p38/JTv-1 (14)
accumulation and kainate-induced excitotoxicity (15).
Additionally, parkin also confers neuronal resistance towards
stimuli that promote mitochondria-dependent apoptosis and
dopamine-mediated toxicity (16,17). Given the multipurpose
neuroprotective roles of parkin, it is conceivable that any
depletion in the level or activity of parkin would significantly
compromise neuronal survivability. Indeed, familial PD-
linked mutations of parkin frequently lead to a reduction or
ablation of parkin catalytic competency (18,19). Similarly,
the inhibition of parkin activity by BAG5 enhances dopamine
neuron death in an in vivo model of PD (20). Conversely,
animals with overexpressed parkin have reduced a-synuclein-
induced neuronal pathology compared with normal control
animals (21,22).
Recently, we demonstrated that parkin solubility in the
brain becomes altered with age (23). As parkin appears to
function as a broad-spectrum neuroprotectant, the resulting
increase in parkin insolubility with age may underlie the pro-
gressive susceptibility of the neurons to stress. Interestingly,
we also observed that many familial PD-linked mutations of
parkin produce alterations in its solubility in a manner that
is highly reminiscent of our observations with the aged brain
(24,25). The converging effects on parkin brought about by
aging and PD-causing mutations are probably not trivial and
suggest that age-dependent modulators affecting the parkin
protein in the same way caused by clinically relevant
parkin mutations would increase an individual’s risk of
developing PD.
Here we used both cellular and animal models to investigate
the effects of various environmental and intrinsic factors that
are linked to PD on parkin solubility. We found that several
of these stressors induce alteration in parkin solubility and
result in its intracellular aggregation. Furthermore, the
depletion of soluble, functional forms of parkin is associated
with reduced proteasomal activities and increased cell death.
Interestingly, we also observed variations in parkin distri-
bution in post-mortem human PD brains relative to normal
controls, which provide further support to our findings.
Taken together, our results suggest that conditions promoting
parkin insolubility compromise parkin’s protective function
and predispose the neurons to degeneration when they are
exposed to continual stress.
RESULTS
Various PD-linked stressors induce changes in
parkin solubility
To facilitate our investigation on the effects of exogenous
modulators on parkin solubility, we have generated SH-
SY5Y neuroblastoma cells stably expressing FLAG-tagged
parkin (SH-Parkin) or containing vector alone as a control
(SH-Vector). Three individual parkin-positive clones
(numbers 1, 2 and 6) were selected for our experiments to
minimize clonal variation. All of these parkin-positive
clones express parkin at a much higher level when compared
with vector control or parental cells but are otherwise similar
morphologically (Fig. 1A and B). Using the sequential frac-
tionation method described in Materials and Methods, we
observed that the majority of the expressed FLAG-parkin
resides in the detergent-soluble (S) fractions (Fig. 1C).
As the treatment of cells with an acute dose (20 mM) of
hydrogen peroxide (H2O2) has previously been shown by
Winklhofer et al. (26) to induce parkin to adopt a detergent-
insoluble conformation, we initially performed the earlier
mentioned experiment with our parkin stable cell lines to
see if we could reproduce the observed effect on parkin. Con-
sistent with Winklhofer’s finding, we observed a significant
shift in parkin extractibility towards the detergent-insoluble
(P) fractions following H2O2-induced oxidative stress
(Fig. 1C). We also treated the cells with lower concentrations
of H2O2 (2–10 mM) and recorded essentially the same obser-
vations (data not shown). Interestingly, treatment of cells with
the proteasome inhibitor, MG-132, led to a similar shift in
parkin extractibility (Fig. 1C). Thus, both oxidative and pro-
teolytic stress appear to be capable of modifying parkin
solubility.
We have recently described the S-nitrosylation of parkin in
sporadic PD (27). To examine whether nitrosative stress
induces a similar effect on parkin solubility observed earlier,
we treated SH-Parkin cells with NOC-18, an NO-donor we
have previously described to be effective in bringing about
the S-nitrosylation of parkin (27). Although the treatment of
SH-Parkin cells with 100 mM of NOC-18 for 24 h did not sig-
nificantly alter its solubility (data not shown), the amount of
detergent-soluble parkin showed a dramatic relocalization to
the P-fractions when a higher amount (500 mM) of NOC-18
was used to treat the cells (Fig. 1D). NO assays performed with
2,3-diaminonapthalene revealed that parkin is S-nitrosylated
more prominently in cells treated with 500 mM NOC-18 than
those treated with 100 mM NOC-18 (Fig. 1E). These results
suggest that the S-nitrosylation of parkin could alter the
protein solubility in a manner that mirrors that induced by
H2O2 and MG-132.
We next examined the effects of treating the parkin
stable cell lines with the parkinsonian neurotoxins, MPPþ,
rotenone and 6-hydroxydopamine (6-OHDA), because these
agents are well known to trigger oxidative stress and selective
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dopaminergic neuronal death in injected animals. Not surpri-
singly, treatment of the SH-Parkin cells with all the three
neurotoxins resulted in a significant population of parkin
being shifted to the P-fractions (Fig. 2A). These neurotoxin-
mediated alterations in parkin solubility appear to be dose-
and time-dependent. In all three cases, a progressive shift in
parkin extractibility from the S- to the P-fractions was appar-
ent with increasing dose of the neurotoxic treatment (Fig. 2B)
(data not shown for 6-OHDA). Although the solubility of
parkin was relatively unaffected at lower doses of these
neurotoxins, prolonging the treatment at these doses for a
few days likewise led to a shift in parkin extractibility
towards detergent insolubility (Supplementary Material,
Fig. S1) (Fig. 4C).
Expectedly, we observed a similar alteration in parkin solu-
bility, as previously described, when the stable cell lines were
treated with the PD-linked herbicide, paraquat, as well as with
the metal, iron (Fe2þ) (Fig. 2C). Further, we also examined the
Figure 1. Effects of oxidative, proteolytic and nitrosative stress on parkin stable cell lines. (A) Phase-contrast images of normal SH-SY5Y neuroblastoma cells
and three individual clones stably expressing FLAG-tagged parkin (nos 1, 2 and 6) showing no apparent difference in their morphology. (B) Anti-FLAG and anti-
parkin immunoblots of total cell lysates prepared from normal SH-SY5Y (2), SH-Vector (V) and the parkin stable clones (nos 1, 2 and 6). (C and D) Anti-FLAG
immunoblots of cell extracts sequentially prepared with Triton X-100 (S) and SDS (P) from untreated parkin stable cell lines or those treated either with 20 mM
H2O2 (30 min), 1 mM MG-132 (16 h) or 0.5 mM NOC-18 (24 h) as indicated. Equal loading of the different cell lysates was verified by anti-b-actin immuno-
blotting. (E) Bar graph showing S-nitrosylated parkin as detected by a fluorometric method described by Chung et al. (27). Anti-FLAG immunoblot (inset) shows
equivalent amount of FLAG-parkin immunoprecipitated. These results represent mean+ SEM of five separate experiments. P , 0.05, P , 0.001 versus
control group (one-way ANOVA).
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effects of dopamine treatment on parkin solubility properties
because dysregulated dopamine homeostasis is known to
cause significant endogenous stress (28). Consistent with our
earlier observations, the translocation of soluble parkin into
the detergent-insoluble fractions following dopamine treat-
ment of SH-Parkin cells occurs in a dose-dependent manner
(Fig. 2D). Taken together, our results suggest that various
forms of cellular stress, originating both exogenously and
endogenously, could modify parkin structure and lead to its
misfolding, thereby altering the protein solubility. Supporting
this, we could reproduce our earlier observations by treating
the SH-Parkin cells with canavanine (29), an amino acid
analog that promotes protein misfolding by substituting for
arginine during translation (Fig. 2C). Presumably, misfolded
parkin aggregates and becomes resistant to normal detergent
extraction.
Figure 2. Stress-induced alterations in parkin solubility. Anti-FLAG immunoblots of cell extracts sequentially prepared with Triton X-100 (S) and SDS (P) from
untreated parkin stable cell lines or those treated with the indicated doses of (A) rotenone (24 h), MPPþ (24 h), 6-OHDA (3 h). (C) Paraquat (24 h), iron and
canavanine (16 h). (B and D) Anti-FLAG immunoblots of cell extracts similarly prepared showing a dose-dependent shift in parkin solubility towards the
P-fractions following rotenone, MPPþ and dopamine treatment (20 h), as indicated. Equal loading of the different cell lysates was verified by anti-b-actin
immunoblotting. Each of these experiments was repeated at least three times.
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Stress-induced alterations in parkin solubility promote
parkin aggregation
To investigate if stress-induced alteration in parkin solubility is
associated with its propensity to form intracellular aggregates,
we examined the localization of FLAG-parkin in untreated SH-
Parkin cells as well as in cells treated with rotenone, MPPþ
and paraquat. As the percentage of cell death is markedly
increased at acute doses of these toxins, we performed our
localization studies here with lower doses of these stressors
in order to reduce the amount of cell death. Consistent with
our previous report (24,25), we found that parkin in untreated
cells is uniformly expressed throughout the cytoplasm
(Fig. 3). In SH-Parkin cells treated with the parkinsonian
neurotoxins rotenone and MPPþ at their respective dose that
would produce alteration in parkin solubility (Supplementary
Material, Fig. S1) (Fig. 4C), we observed prominent parkin
aggregates within the cell, which accumulate in the perinuclear
region (Fig. 3). Similarly, treatment of SH-Parkin cells with
paraquat produced FLAG-parkin positive inclusions. These
results are reminiscent of our previous observation that
parkin mutations that alter the protein solubility tend to
trigger its intracellular aggregation (24,25). Our results here
show that stress-induced alteration in parkin solubility simi-
larly results in parkin’s tendency to aggregate within the cell.
Stress-induced alterations in parkin solubility
compromise parkin’s protective function
It is conceivable that the changes in parkin solubility trigger-
ing its aggregation could deplete the cell of soluble functional
parkin and concomitantly compromise parkin’s protective
function. To enable us to ascertain this, we treated the
SH-Parkin and control cells with the lipid-soluble neurotoxin,
rotenone, to first establish parkin’s potential protective
effects towards this neurotoxic insult. For this experiment,
we treated the cells with low doses of rotenone to better reca-
pitulate the slow progression of dopaminergic neuronal death
in PD. After 6 days of chronic rotenone treatment, especially
at the 25 and 50 nM doses, we noticed a dramatic morpho-
logical difference between the SH-Parkin and control cells
(Fig. 4A). Although a significant population of the SH-
Vector cells at these doses of rotenone treatment became
rounded and reflective, i.e. indicative of dying cells, it is
apparent that the SH-Parkin cells were relatively spared of
these features (Fig. 4A). Quantitative measurement of cell
death at this time point by means of flow cytometry
(Fig. 4B) and Trypan blue exclusion method (data not
shown) correlates well with our morphological observations.
Although we observed some cell death (20%) in the untreated
control cells after 6 days of culture, a significantly higher
average percentage of cell death was evident when these
cells were treated with 25 (50%) and 50 nM rotenone (60%)
(Fig. 4B). Cells expressing exogenous parkin recorded a dra-
matically better survival rate at these doses of rotenone treat-
ment. Indeed, although the average percentage survivability of
SH-Parkin cells at 50 nM rotenone treatment is apparently
reduced when compared with untreated SH-Parkin cells, it is
still significantly better compared with SH-Vector cells
treated with either 50 or even 25 nM rotenone (Fig. 4B). Our
results thus indicate that overexpressed parkin could afford
cellular protection against rotenone-induced cell death.
To examine whether an association exists between the
parkin solubility and the degree of its cellular protection,
Figure 3. Stress-induced alterations in parkin solubility promote the formation of intracellular parkin-positive inclusions. Representative confocal images of
anti-FLAG immunostained (red) parkin stable cells showing uniform cytoplasmic staining in untreated cells and FLAG-positive inclusions (arrows) in cells
treated with the various stressors, as indicated. Anti-FLAG immunostained SH-Vector controls cells showed no background staining.
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we performed anti-parkin or anti-FLAG immunoblotting of
lysates prepared from rotenone-treated or -untreated SH-
Parkin and controls cells. Anti-parkin immunoblotting of
lysates prepared from SH-Vector cells treated with rotenone
at doses above 25 nM reveals a complete shift of the endo-
genous parkin protein to the detergent-insoluble fractions
(Fig. 4C). It is noteworthy that at these doses of rotenone treat-
ment, the control cells showed significantly more cell death
when compared with untreated cells (Fig. 4B). Although a
dose-dependent shift in the population of exogenous parkin
to the detergent-insoluble fractions is also observed in
lysates prepared from rotenone-treated SH-Parkin cells, as
revealed by anti-FLAG immunoblotting, the complete shift
of FLAG-tagged parkin from S- to P-fractions occurred only
at the highest dose of rotenone used (Fig. 4C). At 25 nM rote-
none treatment, a significant population of exogenous parkin
remained in the detergent-soluble fractions, which correlates
with the higher survival rate seen in these cells compared
with their corresponding control cells (Fig. 4B). We obtained
essentially similar results when we repeated the earlier
mentioned experiments with MPPþ in place of rotenone
(Supplementary Material, Fig. S1). Our results thus suggest
that stress-induced relocalization of soluble parkin into
detergent-insoluble fractions is inversely related to the extent
of its cellular protection.
Protective effect of parkin related to its ability to
preserve proteasomal function
We were curious about the mechanism of parkin-mediated cel-
lular protection against rotenone-induced stress and wondered,
in accordance with our recent speculation (30) and also reports
Figure 4. Stress-induced alterations in parkin solubility compromise parkin protective function. (A) Representative phase-contrast images of SH-SY5Y control
cells (SH-Vector) and cells stably expressing parkin (SH-Parkin) showing a dose-dependent increase in the population of rounded, refractile cells 6 days after
treatment with the indicated doses of rotenone. (B) The cell viability was measured and plotted as a bar graph (SH-Parkin nos 1, 2 and 6 depicted by dark,
medium and light shade bars, respectively, and SH-Vector depicted by black bars). Data represent mean+ SEM of three duplicate determinations.
P, 0.05, P, 0.001 versus control group (one-way ANOVA). (C) Anti-parkin and anti-FLAG immunoblots of cell extracts sequentially prepared with
Triton X-100 (S) and SDS (P) from vector and parkin stable cell lines 6 days after treatment with the indicated doses of rotenone. (D) Bar graph showing
the dose-dependent decrease in the chymotrypsin-like proteasome activities of SH-Parkin (nos 1, dark; 2, medium; 6, light shade) and control cells (black)
following 6 days of rotenone treatment relative to their respective untreated counterparts. Data represent mean+ SEM of three duplicate determinations.
P, 0.05, P , 0.001 versus control group (one-way ANOVA).









niversity of Singapore user on 14 D
ecem
ber 2018
by others (11,12), whether parkin could exert its protective
functions by preserving proteasome function in times of cellu-
lar stress. To investigate this, we conducted in vitro proteaso-
mal assays with lysates prepared from rotenone-treated
SH-Parkin and SH-Vector cells as previously described. We
compared the respective extent of proteasomal impairment
in each of these cell types following stress application and
plotted the bar graph accordingly by assigning a single arbi-
trary proteasomal activity unit to each of the untreated cell
types (Fig. 4D). It becomes immediately apparent that there
is a dose-dependent decrease in the proteasome activities in
these cells following their treatment with rotenone (Fig. 4D).
However, at higher doses of rotenone treatment, the SH-
Vector cells appear to be much more susceptible to rote-
none-induced proteasomal impairment among the cell lines
examined (Fig. 4D). Collectively, SH-Parkin clones showed
a statistically higher proteasomal activity when compared
with SH-Vector cells at 25 nM or higher rotenone treatment
(Fig. 4D). The drastic decrease in the proteasomal activities
of control cells at these rotenone doses compared with
untreated cells is consistent with the dramatic increase in
their cell death as described earlier (Fig. 4B). Conversely,
there is an association between the better maintenance of func-
tional proteasomes in SH-Parkin cells and the greater surviva-
bility of these cells in times of stress (compare Fig. 4B and D).
Our results therefore strengthen the suggestion that one
mechanism by which parkin could afford cellular protection
against stress-induced cell death is through the preservation
of proteasomal activity (11,12,30).
Familial PD-linked parkin mutations predispose parkin
solubility alterations by stress and compromise its
protective function
We have previously classified familial PD-linked parkin
missense mutants into two broad groups on the basis of
their detergent solubility properties, i.e. detergent-soluble
versus-insoluble mutants (24). Here, we examined the effect
of stress on the properties of the detergent-soluble parkin
mutants. To facilitate our investigation, we generated stable
SH-SY5Y cells expressing the detergent-soluble parkin
A82E (SH-A82E) and T240R mutants (SH-T240R). We then
repeated the experiments described in Figure 4 with these
parkin mutant stable cell lines. After 6 days of chronic rote-
none treatment, detergent-soluble and -insoluble lysates were
prepared from the neurotoxin-treated or -untreated SH-SY5Y
stable cell lines. Following anti-FLAG immunoblotting of
the fractionated lysates, we noticed a dose-dependent shift of
FLAG-parkin into the P-fractions similar to what we have
observed earlier (compare Figs 5A and 4C). Interestingly,
both the parkin mutants examined appear to be more suscep-
tible to rotenone-induced solubility alteration (Fig. 5A).
Although the wild-type FLAG-tagged parkin apparently
shifted completely to the P-fractions at 50 nM rotenone
Figure 5. Familial PD-linked parkin mutants predispose parkin to stress-induced solubility alterations. (A) Anti-FLAG immunoblots of cell extracts sequentially
prepared with Triton X-100 (S) and SDS (P) from wild-type and mutant parkin stable cell lines 6 days after treatment with the indicated doses of rotenone. (B)
Bar graph showing the percentage cell viability in SH-Parkin WT (dark shade), SH-Parkin A82E (medium shade), SH-Parkin T240R (light shade) and SH-Vector
(black) measured at 6 days after rotenone treatment. Data represent mean+ SEM of three duplicate determinations. P, 0.05, P, 0.001 versus control
group (one-way ANOVA). (C) Anti-HA and anti-myc immunoblots of synphilin immunoprecipitates (IPmyc) prepared from SH-SY5Y cells transfected with
myc-tagged synphilin-1 in the presence of HA-tagged ubiquitin without or with the various FLAG-tagged parkin forms. Lysates prepared from these variously
transfected cells were also subjected to anti-myc or anti-FLAG immunoblotting to show their expression (INPUT). These experiments were duplicated. (D) Bar
graph showing the dose-dependent decrease in the chymotrypsin-like proteasome activities of SH-Parkin WT (dark shade), SH-Parkin A82E (medium shade),
SH-Parkin T240R (light shade) and SH-Vector (black) following 6 days of rotenone treatment relative to their respective untreated counterparts. Data represent
mean+ SEM of three duplicate determinations. P, 0.05, P, 0.001 versus control group (one-way ANOVA).
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treatment, the phenomenon occurs at earlier rotenone doses,
i.e. 25 and 10 nM, respectively, for the A82E and T240R
parkin mutants (Fig. 5A). Quantitative measurement of cell
death in these rotenone-treated cell lines reveals that stable
SH-SY5Y cell lines expressing the parkin T240R mutant
are as susceptible to neurotoxin-induced cell death as the
SH-Vector control (Fig. 5B). Associated with this, the protea-
some activities in the SH-T240R cells, relative to SH-Vector
control, showed no enhanced resistance to impairment
caused by the treatment (Fig. 5D). In contrast, the A82E
parkin mutant afforded significant cellular protection against
cell death and proteasomal impairment brought about by the
neurotoxin. However, at 25 nM rotenone treatment, where
the A82E mutant relocalizes completely to the P-fraction, its
protective effects decrease significantly compared with wild-
type FLAG-parkin (Fig. 5B and D).
Although the degree of cellular protection afforded by these
parkin mutants correlates well with their propensity to become
directed to the detergent-insoluble fractions in the presence of
rotenone, it is apparent that their respective catalytic compe-
tency plays a deterministic role in improving the survivability
of cells that express them. To examine their enzymatic activity
relative to wild-type parkin, we conducted in vivo ubiquitina-
tion assays using synphilin-1, a known parkin target, as a
substrate. Consistent with our previous report (19), the
parkin T240 mutant exhibited a significantly reduced catalytic
activity compared with wild-type parkin (Fig. 5C). In contrast,
the A82E mutant ubiquitinates synphilin-1 almost as effi-
ciently as wild-type parkin (Fig. 5C). Taken together, our
results support the importance of parkin catalytic activity for
its protective functions and at the same time suggest that the
higher propensity of soluble parkin mutants to stress-induced
alteration is an alternative mechanism underlying their dys-
function, particularly for those mutants that retain substantial
catalytic activity.
Parkin solubility alterations in the brains of
MPP1-treated mice
To extend our earlier mentioned cell culture studies further, as
well as to investigate the physiological relevance of parkin
solubility alterations following neurotoxic stress, we examined
the effects of MPPþ on the biochemical distribution of mouse
brain parkin in vivo. We performed anti-parkin immuno-
blotting of detergent-soluble and -insoluble lysates prepared
from the ventral midbrain and striatal regions of mice
treated with an acute paradigm of MPPþ. Consistent with
our cellular studies described earlier, we observed a time-
dependent increase in the amounts of insoluble parkin in
both the ventral midbrain (Fig. 6A) and striatal regions
(Fig. 6B) of mice after the last MPPþ treatment following
an acute intoxication paradigm. Significant amounts of insolu-
ble parkin immunoreactivity started appearing at 24 and 48 h
post-MPPþ injection in the ventral midbrain and striatal prep-
arations, respectively, and persisted through the time course
examined (Fig. 6A and B). Interestingly, the level of soluble
striatal parkin increased transiently at 24 h post-MPPþ injec-
tions and its subsequent decrease corresponded to the appear-
ance of the insoluble forms (Fig. 6B). The results we gathered
from our cell culture and animal studies here are thus in
general agreement with each other and collectively point
towards the pathophysiological relevance of altered parkin
function associated with its modification by PD-linked
stressors.
Variations in parkin distribution between normal and
PD human brains
Previously, we have demonstrated an age-dependent decrease
in parkin solubility in human brains (23). Given the neuro-
protective roles of parkin, we wondered whether the aging
brain undergoing stress linked to PD would respond by elevat-
ing its levels of parkin to counteract the protein depleted into
the insoluble fraction. The replacement of soluble parkin
would be conceivably important in helping the brain mitigate
the ill effects posed by the insults and concomitantly prolong
its neuronal survival. Accordingly, we performed anti-parkin
immunoblotting with detergent-soluble and -insoluble lysates
prepared from post-mortem normal and PD human brains.
The mean age of these samples is 83.6 and 81.5 years, respect-
ively (Table 1). The sequential detergent extraction procedure
used to extract the brain tissues, as described in Materials and
Methods, is similar to the one we have described previously
(23), except that 1% (instead of 2%) SDS was used in our
final extraction. Consistent with our previous report (23), we
observed a dramatic relocalization of brain parkin from
the detergent-soluble to the detergent-insoluble fractions in
the caudate and cingulate cortex regions from control brains
(Fig. 7). Although the amount of detergent-insoluble parkin
Figure 6. Significant increase in detergent-insoluble parkin in the mouse brain
following MPPþ treatment. Detergent-soluble and -insoluble fractions of
brain lysates prepared from (A) ventral midbrain and (B) striatum of mice
after treatment with MPPþ for 2, 4, 24, 48, 72 and 96 h were subjected to
SDS–PAGE and immunoblotted with anti-parkin and anti-actin antibodies.
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associated with the samples from PD brains are expectedly
significantly higher than those derived from control brains
(Fig. 7), the phenomenon could be related to a remarkable cor-
responding increase in soluble parkin levels in the majority of
the PD brains. Although the average amount of detergent-
insoluble parkin in PD brains increased by 16% over their
control counterparts, the mean elevation of soluble parkin in
PD brains is a dramatic 2.5-fold in the PD brains relative to
their controls (Fig. 7). It would thus appear that an increase
in endogenous parkin level in the brain accompanies the
disease, presumably to counter the loss of the protein into
insoluble pools in a bid to preserve neuronal survivability.
DISCUSSION
Although the debate surrounding the respective roles of
environmental and genetic factors in the etiology of sporadic
PD has persisted since the disease was first described in the
early 19th century, current evidence favors a synergistic inter-
action between exogenous toxic agents and endogenous
elements in bringing about the neurodegenerative process
(1,31). Indeed, several reports have demonstrated a pathogenic
relationship between the environmental stress factors and the
PD-linked gene product, a-synuclein (32–34). In our current
report, we show that several environmental stress factors
linked to PD, as well as endogenous dopamine, produce altera-
tions in parkin solubility and concomitantly compromise its
protective function. Our results therefore further strengthen
the relationship between environmental factors and genetic
susceptibilities in the development of PD.
In recent years, it has become increasingly clear that parkin
plays a pivotal role in maintaining dopaminergic neuronal
survivability. We have previously demonstrated that familial
PD-linked mutations in parkin led to its dysfunction either
through direct catalytic impairment or through the alteration
of the protein’s structural and biochemical properties, leading
to a decrease in its detergent solubility (18,19,24,25). Hence, it
is conceivable that exogenous and/or endogenous factors that
affect parkin in a way that mirrors the impact of parkin
mutations on the protein would increase the vulnerability of
dopaminergic neurons to degenerate. Interestingly, brain
parkin becomes progressively more detergent-insoluble with
normal aging (23). As age represents an unequivocal risk
factor for PD, the depletion of soluble parkin with age is unli-
kely to be a trivial association. We believe that age-mediated
parkin solubility changes are likely a cumulative event pro-
moted by the continuous spectrum of insults experienced by
the brain throughout its lifetime. Shedding some light on
these, our results indicate that oxidative, nitrosative and
proteolytic stress could modify parkin in a manner analogous
to that mediated by several of its clinically relevant mutations,
as well as by normal aging. The resulting relocalization of
detergent-soluble parkin into insoluble fractions suggests
that one mechanism of environmental neurotoxicity triggering
the demise of dopaminergic neurons in PD is through the
progressive depletion of soluble functional parkin.
As parkin functions as a broad-spectrum neuroprotectant,
the susceptibility of the stress-prone dopaminergic neu-
rons to degeneration in the absence of functional parkin is
easy to comprehend. This is indeed the case with our cell
culture studies described earlier. Although overexpressed
parkin helps the SH-SY5Y neuroblastoma cells mitigate exter-
nally applied stress (rotenone and MPPþ) rather effectively, it
could do so only until a point, beyond which soluble parkin
becomes fully depleted and could afford no extra protection
to the cells expressing it. Similarly, the depletion of soluble
endogenous parkin coincides with the onset of significant
rotenone-induced cell death in control cells, suggesting again
that parkin is protective only until a certain point. This
phenomenon is at the same time curiously paradoxical, as it
appears that an important factor chosen by the cell to provide
a critical defense against environmentally triggered stress
would later become the victim itself. An important corollary
to this is that during times of heightened stress, increasing
the level of endogenous parkin expression to counter the loss
of the protein into insoluble pools would help ensure neuronal
survivability. Supporting this, we found that parkin mRNA
expression in SH-SY5Y cells increased several fold in response
to various stressors including rotenone, iron and paraquat (Sup-
plementary Material, Fig. S2). Furthermore, the unfolded
protein stress also promotes the elevation of parkin expression,
which acts to relieve the stress (35). Conceivably, cells that fail
to produce functional parkin in sufficient amount would be less
Table 1. Brain region, diagnosis, age and post-mortem delay
Subjects Brain region Diagnosis Age Post-mortem delay
Control 1 Caudate — 83 5
Control 2 Caudate — 79 10
Control 3 Caudate — 81 20
Control 4 Cingulate — 83 5
Control 5 Cingulate — 92 19
Patient 1 Caudate PD/LB CHG LIMBIC, Porencephalic Cyst 81 8.75
Patient 2 Caudate PD/LB CHG Neocortical 80 19
Patient 3 Caudate PD/LB CHG 84 17.5
Patient 4 Caudate PD/LB CHG Limbic 83 14
Patient 5 Caudate PD/DLB 77 5
Patient 6 Caudate PD/LB CHG Neocortical 84 13
Patient 7 Caudate PD/LB CHG 88 19.5
Patient 8 Caudate PD 73 6
Patient 9 Caudate PD W/Dementia, LBD Neocortical 84 5
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able to cope with stress. In this regard, it is important to note
that the caudate region of the PD brain, where a significant
upregulation of parkin levels occurs (Fig. 7), is relatively
spared from degeneration during the disease progression.
Although it is tempting to think that the selective vulnerability
of dopaminergic neurons seen in sporadic PD may be related to
their failure in replacing cytosolic parkin lost to the insoluble
pool, a more detailed analysis of parkin distribution in different
regions of the PD brains would be required to evaluate this
speculation. Nonetheless, such a scenario remains a formal
possibility. Indeed, a selective loss of the proteasome
a-subunit in the SNc but not in the frontal cortex and striatum
in PD has been recently reported (36). Further, an important
component of the proteasome complex (PA700) failed to upre-
gulate in the SNc, although it occurred in the frontal cortex and
striatum in PD compared with control (36). Our results may
thus help to explain the expanded risk for PD associated with
parkin haploinsufficiency, as well as with normal aging.
Indirectly, our results also support the utility of parkin gene
therapy as a means to mitigate the progression of the disease.
Recently, Jiang et al. (17) demonstrated that overexpression
of parkin in SH-SY5Y cells significantly reduced the amount
of intracellular oxyradicals, suggesting that the protective
effect of parkin is afforded by its ability to suppress oxidative
stress. Consistent with this, we found here that parkin attenu-
ates rotenone-induced cell death. It is evident from our results
that a plausible mechanism responsible for the protective func-
tion of parkin against stress-induced toxicity is through
the preservation of proteasome activity. This is consistent
with previous reports by others (11,12). The maintenance of
a viable proteasome by parkin is clearly dependent on its E3
ligase activity. However, whether parkin-mediated K48-
linked ubiquitination, or a newly described K63-linked ubiqui-
tination activity of parkin (37,38), is required in this protection
is unknown. Interestingly, mutations in parkin that do not
overtly alter the protein activity or solubility appear to pre-
dispose the protein to solubility alteration by environmental
stress. Hence, the A82E parkin mutant afforded significantly
less protection against rotenone-induced toxicity when com-
pared with the wild-type protein, despite having comparable
catalytic activity. In contrast, being catalytic impaired and
even more susceptible to stress-induced alteration than the
A82E parkin mutant, the T240R mutant offers virtually no
protection against rotenone-induced toxicity. Taken together,
our previous (18,19,24,25) and current work on the parkin
mutants demonstrate that mutations in parkin could impair
the protein function in more than one way, including frank
catalytic impairment, direct alteration of the protein solubility
and localization or simply a predisposition to such alterations.
Notably, most, if not all, of the stressors we have used in
this study are associated with oxidative stress. The occurrence
of oxidative stress in PD is consistently supported by both
post-mortem studies and by studies demonstrating the capacity
of oxidative stress and oxidizing toxins to induce nigral cell
degeneration (39). Although a myriad of cellular macro-
molecules could be damaged by oxidative free radicals,
enzymes whose structure and function are dependent on
catalytic cysteine are expected to be more susceptible to
the consequence of oxidative modification. The tyrosine
phosphatase family of enzymes, all of which contain catalytic
Figure 7. Variations in brain parkin distribution between normal and PD individuals. (A) Soluble fractions and (B) insoluble fractions of brain lysates from
caudate (n ¼ 3) and cingulate cortex (n ¼ 2) of control and sporadic PD caudate brains (n ¼ 9) were subjected to SDS–PAGE and immunoblotted with
anti-parkin and anti-actin antibodies. The levels of parkin protein in the (C) soluble and (D) insoluble fractions were normalized to their respective actin
levels and quantified and the results obtained plotted on a histogram (P, 0.05, P, 0.01, Student’s t-test).
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cysteines in their active sites, is one example (40). RING-
finger E3 ligases, such as parkin, are also characterized by
their cysteine-rich catalytic moiety that represent targets for
oxidative modification. Furthermore, we and others have
demonstrated the importance of these RING-finger cysteines
in maintaining the native structure of parkin (24,41–43).
Thus, it is not surprising that several of the stress factors we
have examined could produce alterations in the structural
and biochemical properties of parkin, as they are associated
with the production of oxidative free radicals. Similarly, nitro-
sative modification of parkin has been shown to occur on the
protein’s RING finger cysteines (27,44), which would explain
the associated solubility changes observed. Further, our results
showing that S-nitrosylated parkin’s tendency to adopt a deter-
gent-insoluble conformation would support a negative role for
this type of modification on parkin.
Taken together, our results provide a mechanistic link
between putative etiologic environmental (and endogenous)
factors and dysfunction of a key PD-linked gene product and




The following antibodies were used: polyclonal anti-parkin
(Cell Signalling Technologies), monoclonal anti-Flag per-
oxidase (Sigma, St Louis, MO, USA), monoclonal anti-myc
(Roche, Indianapolis, IN, USA), monoclonal anti-c-myc-per-
oxidase conjugates (Roche), monoclonal anti-HA-peroxidase
conjugate (Roche), monoclonal anti-b-actin (Sigma) and
rhodamine-conjugated anti-mouse IgG (Molecular Probes).
The FLAG-tagged wild-type parkin expression construct was
a kind gift from R. Takahashi and the FLAG-tagged parkin
missense mutants A82E and T240R have been described
previously (24). All other chemicals, unless otherwise stated,
were purchased from Sigma. Stock solutions of the following
chemicals were prepared and stored at 2208C: MG-132 (1 M
in DMSO); rotenone (10 mM in DMSO); MPPþ (10 mM in
dH2O); paraquat (1 M in PBS); canavanine (0.5 M in H2O);
FeCl2 (1 M in 0.1 M HCl); dopamine (0.5 M in H2O
supplemented with 0.1 M vitamin C).
Generation of stable cell lines, preparation of cell lysate
and western blot analysis
SH-SY5Y neuroblastoma cells were transfected with
pCDNA3 plasmid vector alone or bearing the FLAG-tagged
parkin constructs using LipofectAMINE PLUS reagent (Invi-
trogen) according to the manufacturer’s instructions. Two
days later, stably transfected cells were selected for in media
containing 800 mg/ml geneticin (Invitrogen). Subsequently,
at least 20 clonal colonies were picked for each cDNA con-
struct and screened by means of western blot analysis. All
positive cell lines used for the experiments described here
were maintained in serum containing DMEM supplemented
with 200 mg/ml geneticin (Invitrogen) to prevent extrusion
of the integrated constructs. Sequential fractionation of cell
lysates into Triton X-soluble (S) and SDS-soluble (P) fractions
was performed as previously described (24). Equivalent
amount of proteins among different S- and P-fractions was
resolved by means of SDS–PAGE and the levels of various
proteins were analyzed by means of western blotting pro-
cedures using ECL detection reagents (Amersham).
Immunocytochemistry and confocal microscopy
Cellular localization studies of parkin by means of immuno-
cytochemistry and confocal microscopy were performed as
previously described (24). For these studies, parkin stable
cells were either untreated or treated with rotenone (25 or
50 nM for 6 days), MPPþ (200 or 500 mM for 4 days) and
paraquat (1 mM for 4 days). The cells in culture were replaced
with fresh media daily, each containing appropriate dose of the
various stressors.
Cell viability and proteasome activity analysis
Quantitation of cell survival was performed using two
methods: flow cytometry and Trypan blue exclusion assay.
For the flow cytometric analysis, cells were seeded at a
concentration of 1  106/ml. After treatment, cells were
trypsinized and propidium iodide (1 mg/ml) was added 5 min
before flow cytometric analysis by the Coulter imaging
system (BD). A count of 10 000 cells were taken and percen-
tage of cell death was calculated using winMDIv2.8 (BD).
Proteasomal activities after chronic rotenone exposure were
determined by incubating lysates (10–15 mg of protein)
with substrates Suc-LLVY-AMC for 1.5 h at 378C. The
relative amount of AMC released was measured using a
fluorometer equipped with a 380/460 nm filter set (TECAN).
Statistical significance for all the quantitative data obtained
was analyzed using one-way ANOVA (SPSS 13.0)
(P , 0.05, P , 0.001) unless otherwise stated.
Animals and MPP1 injections
All procedures involving animals were approved by and con-
formed to the guidelines of the Institutional Animal Care
Committee of Johns Hopkins University. Eight-week-old
male C57/bl mice (Charles River Laboratories, Wilmington,
MA, USA) (n ¼ 5 per group) received an acute paradigm of
four intraperitoneal injections of MPPþ and HCl (20 mg/kg
free base; Sigma) in saline at 2 h intervals on 1 day and
control mice received equivalent volumes of saline at the
same frequency. Animals were sacrificed by decapitation at
2, 4, 24, 48, 72 and 96 h after the last MPPþ injection and
their ventral midbrain and striata were quickly dissected out
on ice and immediately frozen in 2808C and processed for
western blot analysis.
Human tissues
Human brain tissue was obtained through the brain donation
program of the Morris K. Udall Parkinson’s Disease Research
Center at Johns Hopkins Medical Institutions (JHMI) accord-
ing to HIPAA regulations. This research proposal involves
anonymous autopsy material that lacks identifiers of gender,
race or ethnicity. The JHMI Joint Committee on Clinical
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Investigations decided that the studies in this proposal are
exempt from Human Subjects Approval because of Federal
Register 46.101 exemption number 4.
Preparation of human and mouse brain tissues
Caudate tissues from three control brain and frontal cortical
tissues from two control and nine caudate tissues from PD/
DLB brains were age matched and used to analyze parkin
solubility. Detergent-soluble and -insoluble fractions were
prepared from human brain tissues and mouse brain tissue,
such as ventral midbrain and striatum, by homogenization of
samples in lysis buffer [10 mM Tris–HCl (pH 7.4), 150 mM
NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 10 mM Na-b-glycero-
phosphate, phosphate inhibitor mixture I and II (Sigma),
complete protease inhibitor mixture (Roche)] by using a
Diax 900 homogenizer (Heidolph, Cinnaminson, NJ, USA).
After homogenization, samples were rotated at 48C for
30 min for complete lysis, then the homogenate was centri-
fuged (10 000g, 48C, 20 min) and the resulting pellet and
supernatant fractions were collected. The pellet fractions
were washed once in lysis buffer containing detergent, and
the resulting pellet was solubilized in lysis buffer containing
1% SDS. Protein concentrations of both soluble and insoluble
fractions were determined using the BCA kit (Pierce,
Rockford, IL, USA) with BSA standards and analyzed by
western blot. Western blotting was carried out with anti-
parkin (PRK8 mouse monoclonal) and anti-b-actin (Sigma)
antibodies. Detection was performed with enhanced chemilu-
minescence (Amersham Biosciences, Piscataway, NJ, USA).
Quantitative real-time PCR
Total RNA was isolated from SH-SY5Y cells either untreated
or treated with 50 nM rotenone, 5 mM paraquat or 10 mM iron
for 24 h using the RNAeasy Mini Kit (Qiagen). Subsequently,
the isolated RNA was reverse transcribed using the Super-
script First-Strand Synthesis System (Invitrogen). Real-time
PCR was carried out in a Light Cycler (Roche) using the
FastStart DNA Master Plus Sybergreen I system (Roche)
according to the manufacturer’s protocol. A pair of parkin-
specific primers (forward: 50-GGAAGTCCAGCAGGTAGA
TCA; Reverse: 50-ACCCTGGGTCAAGGTGAG) were gene-
rated for this purpose. Concurrently, real-time PCR with a
primer pair specific for GAPDH (forward: 50-GAAGGT
GAAGGTCGGAGTCAACG; Reverse: 50-TGCCATGGGT
GGAATCATATTGG) was also included in the same run as
an internal control. A single PCR end product was obtained
in each case and the validity of these products was verified
by direct sequencing. Consistent with the role of GAPDH as
a general housekeeping gene, we found no significant change
in its mRNA level during each stress treatment.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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